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Endometrial and ovarian cancer and oral contraceptives - findings in a
large cohort study
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S_q Many case-control studies have shown that oral contraceptives protect against endometrial cancer
and epitheal ovarian cancer, but little information is available from cohort studies. The findings from the
Oxford Family Planning Association contraceptive study are reported here; the relative risks for ever users of
oral contraceptives in comparison with never users were 0.1 (95% confidence interval 0.0-0.7) for endometrial
cancer and 0.4 (95% confidence interval 0.2-0.8) for ovarian cancer. There was a strong negative relationship
between duration of oral contraceptive use and ovarian cancer risk. Thus, in comparison with never users of
oral contraceptives, the relative risk for users of up to 48 months' duration was 1.0 (95% confidence interval
0.4-2.5), while the relative risk for users of 97 months' duration or more was only 0.3 (95% confidence
interval 0.1-0.7).
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A large number ofcase-control studies have shown that oral
contraceptives protect against cancer of the endometrium
(Cancer and Steroid Hormone Study, 1987a; World Health
Organization Collaborative Study, 1988; Hankinson et al.,
1992) and epithelial ovarian cancer (Cancer and Steroid Hor-
mone Study, 1987b; World Health Organization Collabora-
tive Study, 1989; Vessey, 1989). Data from cohort studies,
however, are few. We report here the results obtained from
the Oxford Family Planning Association (Oxford FPA) con-
traceptive study up to October 1993.
Materils and mthos
A detailed description of the methods used in the Oxford
FPA study has been given elsewhere (Vessey et al., 1976). In
brief, 17032 women were recruited at 17 large family plan-
ning cinics in England and Scotland between 1968 and 1974.
At the time of recruitment, each woman had to be (a) aged
25-39, (b) married, (c) white and British, (d) willing to
cooperate and (e) either a current user of oral contraceptives
of at least 5 months' standing or a current user of a dia-
phragm or an intrauterine device of at least 5 months' stand-
ing without previous exposure to the pill. Among other
items, each woman was asked questions at entry to the study
about her date of birth, contraceptive history, social class,
smoking habit, height and weight, obstetric history and past
medical history.
During follow-up, each woman was questioned by a doctor
or nurse at return visits to the clinic and certain items of
information were noted on a special form. These included
details of pregnancies and their outcomes, changes in contra-
ceptive pracics and reasons for the changes, and particulars
of any referrals to hospital as either an out-patient or an
in-patient. Diagnoses on discharge from hospital were
confirmed by obtaining copies ofdischarge letters, summaries
and pathology reports. Women who stopped attending the
clinic were sent a postal version of the follow-up form
annually and, if this was not retumed, were interviewed by
telephone or at a home visit. The work was coordinated by a
part-time research assistant in each clinic and loss to follow-
up because women were untraced or refused to continue to
cooperate was kept down to a rate of about 0.4% per
annum.
Of the 17 032 women in the study, 15 292 remained under
observation on reaching the age of 45. At that age, each
woman was allocated to one of three groups: (a) oral contra-
ceptives never used (5881 women), (b) oral contraceptives
used for a total of 8 years or more (3520 women) and (c)
other durations of oral contraceptive use (5891 women). Only
the women in the two groups first mentioned were followed
up from then on in the detailed way described above.
Accordingly, women in group (c) have been omitted from the
present analysis from the age of 45 onwards.
The analysis is based on the computation of woman-years
of observation in the various groups of interest with the
calation of indirectly standardised rates by the method
described by Vessey et al. (1976). In the analysis of endome-
trial cancer, women in the study were deleted once they had
undergone hysterectomy, while in the analysis of ovarian
cancer women were deleted once they had experinced bi-
lateral oophorectomy. There were 15 endometrial cancers
and 42 epitheial ovarian cancers included in the analysis. It
should be noted that, of the 42 ovarian cancers, five were
judged to be of borderline malignancy while the pathologist
was not absolutely certain that another three were primary
tumours.
Res
We conducted the analyses described below separately for
women aged up to 45 and for women aged 45 or more. The
results in the two sets of analyses were closely similar,
accordingly, we present only the overall figures here.
Of the 15 women with endometrial cancer, only one had
ever used oral contraceptives, resulting in an age-adjusted
relative risk for ever users vs never users of 0.1 (95%
confidence interval 0.0-0.7). Clearly, no more detaied
analysis was possible with such small numbers of cases.
Ovarian cancer risk was strongly related to age, rising
from 4 per 100000 woman-years at ages 25-29 to 41 per
100 000 woman-years at ages 50 or more. The risk of the
disease was also related to parity, the age-adjusted rates
being 29 per 100000 woman-years among nulliparous
women but only 13 per 100 000 woman-years among parous
women. There was no evidence of any association between
ovarian cancer risk and social class, cigarette smoking, age at
first term pregancy or body mass index.
Before examining the relationship between oral contracep-
tive use and ovarian cancer, we tried to assess whether or not
there was any evidence of a protective effect of female
sterilisation against the disease, as has been reported by a
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Table I Epithelial ovarian cancer in relation to total duration of
oral contracptive use
Total duration of Rate per
oral contraceptive No. of 1000X)0 Relative risk (95%
use (months) cases woman-years confidence interval)
Non-user 29 20.2 1.0
Up to 48 6 20.8 1.0 (0.4-2.5)
49-96 2 5.4 0.3 (0.0-1.1)
97+ 5 5.6 0.3 (0.1-0.7)
i) trend 10.0 (P = 0.002). Stanardisd for age (25-29, 30-34,
35-39, 40-44, 45-49, 50+) and parity (nulliparous, parous).
Tablk n Epithelial ovarian cancer in relation to interval since last
use of oral contraceptives
Interval since last Rate per
oral contraceptive No. of 10X)000 Relative risk (95%
use (months) cases woman-years confidence interval)
Non-user 29 20.2 1.0
Up to 48 1 1.7 0.1 (0.0-0.5)
49-96 2 5.6 0.3 (0.0-1.1)
97+ 10 16.1 0.8 (0.4-1.7)
i) heterogeneity 12.0 (P = 0.007). Standardised for age and parity
(see Table I).
number of authors (see Hankinson et al., 1993). We were
unable to detect such an association in our data. Thus, the
age- and parity-adjusted relative risk of ovarian cancer for
erilised women in comparison with non-stefilised women
was 1.5 (95% confidence interval 0.7-3.1).
The age- and parity-adjusted relative risk of ovarian cancer
for ever users vs never users of oral contraceptives was 0.4
(95% confidence interval 0.2-0.8). There was also a clear
negative relationship between duration of oral contraceptive
use and the risk of ovarian cancer (Table 1). This effect was
not apparent among women using oral contraceptives for up
to 4 years, but was strong for longer durations of use.
Table H ex s the association between interval since
last use of oral contraceptives and ovarian cancer risk. The
apparent protective effect was greatest in the recent user
category (within the last 4 years) and was barely apparent in
those who had last used oral contraceptives more than 8
years before.
We were unable to carry out any useful analysis according
to oral contraceptive type in view of the paucity of the
data.
As mentioned in the introduction, a substantial number of
case-control studies have documented an apparent protec-
tive effect of oral contraceptive use against endometrial
cancer. Of these, the two best known are the Cancer and
Steroid Hormone Study (1987a) and the World Health
Organization Collaborative Study (1988). The first of these
studies, conducted in the USA, included 433 cases and 3191
controls. It was found that women who had used combina-
tion oral contraceptives for at least 12 months had an age-
adjusted risk of developing endometrial cancer of 0.6 (95%
confidence interval 0.3-0.9) relative to women who had
never used oral contraceptives. Furthermore, this protective
effect was found to persist for at least 15 years after cessation
of oral contraceptive use. The second (international) study,
which included 130 cases and 835 controls, found that the
relative risk for ever use vs never use of oral contraceptives
was 0.55 (95% confidence interval 0.26-1.17). A number of
other case-control studies, all suggesting a protective effect,
have been summarised by Vessey (1989).
The few data available from cohort studies have given
similar results. In the Walnut Creek Contraceptive Drug
Study (Ramcharan et al., 1981), there were 18 cases of
endometrial cancer in the ever user group and 40 in the never
user group, giving a relative risk of 0.6 (95% confidence
interval 0.3-0.9). The Royal College of General Practitioners
Oral Contraception Study (Beral et al., 1988) found two
cases of 'cancer of the uterus except cervix' in ever users of
oral contraceptives and 16 in never users, resulting in a
relative risk of 0.2 (95% confidence interval 0.0-0.7).
Clearly, our findings match very closely with those of the
Royal College; although both studies suggest a very marked
protective effect of oral contraceptives against endometrial
cancer, the confidence limits indicate consistency with other
results.
The literature concerning a protective effect of oral con-
traceptives in relation to epithelial ovarian cancer is more
extensive than that relating to endometrial cancer. Hankin-
son et al. (1992) have provided a recent overview of 20
studie. They reported that the summary relative risk
associated with ever use of oral contraceptives was 0.64 (95%
confidence interval 0.57-0.73). In addition, the risk of
ovarian cancer decreased with increasing duration of oral
contraceptive use so that there was a 50% decrease in risk
after 5 years' use. This reduced risk appeared to persist at
least 10 years after cessation of use. Thus, compared with
never users, women who had stopped using oral contracep-
tives 10 or more years before had a summary relative risk of
0.60 (95% confidence interval 0.42-0.86).
As with endometrial cancer, the data about oral contracep-
tives and ovarian cancer from cohort studies are few. Willet
et al. (1981) reported an ever use vs never use relative risk of
0.8 (95% confidence interval 0.4-1.5) in the American
Nurses Health Study based on 34 cases in never users and 13
in ever users. In the Walnut Creek Contraceptive Drug Study
(Ramcharan et al., 1981) the corresponding relative risk was
0.4 (95% confidence interval 0.1-1.0) based on 12 cases in
never users and four cases in ever users. The numbers of
cases in the Royal College of General Practitioners Oral
Contraception Study were also small - 12 in the ever user
group and 18 in the never user group (Beral et al., 1988). The
corresponding relative risk was 0.6 (95% confidence interval
0.3-1.4). Our results are an important addition to the cohort
study literature on ovarian cancer and provide further (and
statistically significant) evidence of a protective effect of oral
contraceptive use. There are only two features of our data
which are slightly disturbing; first, no protective effect was
apparent until oral contraceptives had been used for more
than 4 years and, second, there was evidence of some reduc-
tion in the benefit with increasing interval since last use of
oral contraceptives. These observations are, however, based
on small numbers and clearly do not contradict the overview
findings reported by Hankinson et al. (1992).
While a beneficial effect of oral contraceptives with respect
to endometrial cancer is important, the similar effect with
respect to ovarian cancer is even more so since ovarian
cancer is such a deadly disease. It is encouraging to note that
in several countries a decline in the mortality from ovarian
cancer in women under 55 years has been noted since the
early 1970s (Mant and Vessey, 1994). This may well reflect
an effect of oral contraceptive use.
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